// App-Quantinova.ai

: Immune Checkpoints Involving the PD-1/PD-L1/L2 and CD73/A2aR Axes and the Immunosuppressive Microenvironment in DLBCL

Researchers

Presenter

  • Xianhuo Wang

Principal Investigators

  • Tingting Zhang

  • Hengqi Liu

  • Sicong Zhang

  • Lanfang Li

  • Lihua Qiu

  • Zhengzi Qian

  • Shiyong Zhou

  • Kai Fu

  • Huilai Zhang

Medical Centers

  • Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

  • Pathology, Univ. of Nebraska Medical Ctr., Omaha, NE

  • Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China

Locations

  • China

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

Biomarkers

  • 5'-nucleotidase

  • Programmed cell death protein 1

  • Programmed death-ligand 1

  • Cluster of differentiation 8A

Drug/Treatment

  • Adenosine

  • Adenosine Intravenous

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved